Grundläggande statistik
| CIK | 1515740 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Premier Biomedical, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number:000-5463 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Amendment No. 1) SEC FILE NUMBER: 000-54563 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on F |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporat |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54563 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transit |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) 2 |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 1, 2020 |
Annual Report - AMENDMENT NO 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54563 |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2019 ☐ Transition report on Form 10-K ☐ Transition report on Form 20-F ☐ Transition report on Fo |
|
| May 15, 2020 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT EXHIBIT 4.11 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following is a brief description of shares of common stock (“common stock”) of Premier Biomedical, Inc. (the “Company,” “we,” “us,” or “our”). The brief description is based upon our Articles of Incorporation, including the Certificate of Amendment to our Articles of Incorporation, (as amended, our “Articles |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54563 Premier Biomedical, |
|
| May 14, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2020 |
THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT Exhibit 10.3 THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT This THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of the 11th day of May, 2020, by and between Marv Enterprises, LLC a Limited Liability Company organized and existing under the laws of the Commonwealth of Pennsylvania (“Marv”) with an address of P.O. Box 1332, Hermitage, PA 16148 and Premier Biomedical |
|
| May 14, 2020 |
INTELLECTUAL PROPERTY AGREEMENT Exhibit 10.2 INTELLECTUAL PROPERTY AGREEMENT This Intellectual Property Agreement (this “Agreement”) is entered into on May 12, 2020 (“Effective Date”), concerning the pursuits set forth herein for the collective development, implementation and commercialization of a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the “Joint Venture” |
|
| May 14, 2020 |
TECHNOLOGY ACQUISITION AND FINANCING AGREEMENT Exhibit 10.1 TECHNOLOGY ACQUISITION AND FINANCING AGREEMENT This Technology Acquisition and Financing Agreement (this “Agreement”) is entered into on May 12, 2020 (the “Effective Date”) for the collective acquisition, development, financing, implementation and commercialization of certain technologies that may be a potential treatment for the COVID-19 virus and its effects on the human body (colle |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) 27 |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission F |
|
| January 8, 2020 |
BIEI / Premier Biomedical Inc RW - - RW January 7, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N. |
|
| December 10, 2019 |
BIEI / Premier Biomedical Inc S-1 - Registration Statement - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 9, 2019 Registration No. |
|
| November 26, 2019 |
BIEI / Premier Biomedical Inc DEF 14C - - DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) [ X ] Definitive Information Statement PREMIER BIO |
|
| November 14, 2019 |
BIEI / Premier Biomedical Inc PRE 14C - - PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [ X ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) [ ] Definitive Information Statement PREMIER BIO |
|
| November 14, 2019 |
BIEI / Premier Biomedical Inc 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIE |
|
| October 9, 2019 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 26, 2019 (the “Execution Date”), is entered into by and between PREMIER BIOMEDICAL, INC., a Nevada corporation (the “Company”), and GREEN COAST CAPITAL INTERNATIONAL SA, a Panama Corporation (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not |
|
| October 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| October 9, 2019 |
Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| October 9, 2019 |
Exhibit 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of October 3, 2019 (the “Execution Date”), by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and Green Coast Capital International SA, a Panama Corporation (the “Investor”). RECITALS WHEREAS, the parties desire that, upon the terms and subject to the conditions c |
|
| September 17, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Num |
|
| August 21, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number |
|
| August 14, 2019 |
BIEI / Premier Biomedical Inc 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER |
|
| August 13, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission F |
|
| August 6, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) |
|
| August 6, 2019 |
Exhibit 99.1 Premier Biomedical Signs Joint Venture Agreement With New Earth Development, RushNet Inc., and XYZ Hemp, Inc. to Market New Anti-Addiction Patch Tuesday, July 30, 2019 10:00 AM JACKSON CENTER, PA / ACCESSWIRE / July 30, 2019 / Premier Biomedical, Inc. (OTCQB: BIEI) announced today the signing of an agreement forming a joint venture with New Earth Development Corporation, RushNet, Inc. |
|
| July 9, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) 2 |
|
| June 24, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 15, 2019 |
BIEI / Premier Biomedical Inc 10-Q Quarterly Report QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIE |
|
| April 29, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) |
|
| April 22, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2019 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Number) |
|
| April 15, 2019 |
EXHIBIT 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 23, 2018, between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| April 15, 2019 |
BIEI / Premier Biomedical Inc ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54563 Premier Biomedical, Inc. |
|
| April 3, 2019 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 28, 2019 Date of Report (Date of earliest event reported): PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2019 |
BIEI / Premier Biomedical Inc NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2018 ☐ Transition report on Form 10-K ☐ Transition report on Form 20-F ☐ Transition report on Fo |
|
| November 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2018 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 000-54563 (Commission File Numb |
|
| November 29, 2018 |
Certificate of Designation of Series B Convertible Preferred Stock Exhibit 3.1 CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF PREMIER BIOMEDICAL, INC. The undersigned, William A. Hartman, does hereby certify that: A. He is the President of Premier Biomedical, Inc., a Nevada corporation ( |
|
| November 26, 2018 |
8% CONVERTIBLE PROMISSORY NOTE DUE OCTOBER 31, 2018 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| November 26, 2018 |
8% CONVERTIBLE PROMISSORY NOTE DUE OCTOBER 31, 2018 Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| November 26, 2018 |
BIEI / Premier Biomedical Inc QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PR |
|
| November 14, 2018 |
BIEI / Premier Biomedical Inc NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: 000-54563 Washington, D. |
|
| August 20, 2018 |
Exhibit 3.1 |
|
| August 20, 2018 |
BIEI / Premier Biomedical Inc QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER BIO |
|
| August 15, 2018 |
BIEI / Premier Biomedical Inc NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: 000-54563 Washington, D. |
|
| July 11, 2018 |
523,000 shares of common stock Filed pursuant to Rule 424(b)(3) Registration No. 333-224454 PROSPECTUS 523,000 shares of common stock This prospectus relates to the sale by the selling shareholders identified in this prospectus, or their assigns (each a “Selling Shareholder” and collectively the “Selling Shareholders”) of up to an aggregate of 523,000 shares of our common stock. The Selling Shareholders may sell the shares usin |
|
| July 9, 2018 |
BIEI / Premier Biomedical Inc FORM S-1/A S-1/A 1 bieis1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on July 9, 2018 Registration No. 333-224454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or oth |
|
| July 9, 2018 |
BIEI / Premier Biomedical Inc FORM S-1/A As filed with the Securities and Exchange Commission on July 9, 2018 Registration No. |
|
| July 6, 2018 |
BIEI / Premier Biomedical Inc CORRESP CORRESP 1 filename1.htm July 6, 2018 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-224454 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned President of Premier Biomedical, Inc. hereby r |
|
| June 29, 2018 |
BIEI / Premier Biomedical Inc FORM S-1/A As filed with the Securities and Exchange Commission on June 29, 2018 Registration No. |
|
| June 29, 2018 |
BIEI / Premier Biomedical Inc POS AM POS AM 1 bieiposam.htm POS AM As filed with the Securities and Exchange Commission on June 29, 2018 Registration No. 333-220268 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-263566 |
|
| June 29, 2018 |
BIEI / Premier Biomedical Inc CORRESP CORRESP 1 filename1.htm June 29, 2018 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Christine Westbrook Re: Premier Biomedical, Inc. Registration Statement on Form S-1 Filed April 24, 2018 Amendment No. 2 to Registration Statement on Form S-1 Filed June 15, 2018 File No. 333-224454 Dear Ms. Westbrook: The following re |
|
| June 15, 2018 |
BIEI / Premier Biomedical Inc FORM S-1/A As filed with the Securities and Exchange Commission on June 15, 2018 Registration No. |
|
| June 15, 2018 |
BIEI / Premier Biomedical Inc CORRESP CORRESP 1 filename1.htm June 15, 2018 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Christine Westbrook Re: Premier Biomedical, Inc. Registration Statement on Form S-1 Filed April 24, 2018 Amendment No. 1 to Registration Statement on Form S-1 Filed April 30, 2018 File No. 333-224454 Dear Ms. Westbrook: The following r |
|
| June 4, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 23, 2018 |
BIEI / Premier Biomedical Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER BI |
|
| May 15, 2018 |
BIEI / Premier Biomedical Inc NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: 000-54563 Washington, D. |
|
| May 4, 2018 |
BIEI / Premier Biomedical Inc DEF 14A DEF 14A 1 bieidef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted |
|
| May 3, 2018 |
BIEI / Premier Biomedical Inc PRER 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 30, 2018 |
BIEI / Premier Biomedical Inc FORM S-1/A S-1/A 1 bieis1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on April 30, 2018 Registration No. 333-224454 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or o |
|
| April 26, 2018 |
EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William A. Hartman and John Borza, and each of them, his or her true and lawful attorneys-in-fact and agents, each acting alone, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all c |
|
| April 26, 2018 |
BIEI / Premier Biomedical Inc FORM S-1 S-1 1 bieis1.htm FORM S-1 As filed with the Securities and Exchange Commission on April 24, 2018 Registration No. 333-[•] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or other jurisdiction of incorp |
|
| April 19, 2018 |
BIEI / Premier Biomedical Inc PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| April 12, 2018 |
EXHIBIT 10.62 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 1, 2018, between Premier Biomedical Inc., a Nevada corporation (the “Company”), and the purchasers signatory hereto (each a “Holder” and collectively the “Holders”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, |
|
| April 12, 2018 |
Form of 8% Convertible Promissory Note, dated March 1, 2018 EXHIBIT 10.60 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| April 12, 2018 |
BIEI / Premier Biomedical Inc FORM 10-K (Annual Report) 10-K 1 biei10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-5 |
|
| April 12, 2018 |
EXHIBIT 10.61 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 1, 2018, between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| April 2, 2018 |
BIEI / Premier Biomedical Inc NT 10-K NT 10-K 1 bieint10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2017 ¨ Transition report on Form 10-K ¨ Transition report on Form 20-F ¨ Transit |
|
| March 5, 2018 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2018 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 28, 2017 |
8-K 1 biei8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2017 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of |
|
| December 13, 2017 |
biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| December 5, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2017 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| November 21, 2017 |
Form of 8% Convertible Promissory Note, dated August 8, 2017 EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| November 21, 2017 |
Amendment No. 1 of the Registration Rights Agreement, dated August 4, 2017 EXHIBIT 10.3 AMENDMENT NO. 1 REGISTRATION RIGHTS AGREEMENT This First Amendment to the Registration Rights Agreement (this “Amendment”) is entered into on August 4, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (including its successors and assigns, the “Purchaser” and collectively with all other purchasers in the s |
|
| November 21, 2017 |
BIEI / Premier Biomedical Inc FORM 10-Q (Quarterly Report) 10-Q 1 biei10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission |
|
| November 21, 2017 |
Form of Exchange Agreement, dated August 4, 2017 EXHIBIT 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into on August 8, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”) and [●] (the “Shareholder”). Any capitalized terms not defined herein shall have the meaning given to such term in the Securities Purchase Agreement. RECITALS WHEREAS, pursuant to a Securities Purchase Agreement b |
|
| November 21, 2017 |
Amendment No. 1 of the Securities Purchase Agreement, dated August 8, 2017 EXHIBIT 10.4 AMENDMENT NO. 1 SECURITIES PURCHASE AGREEMENT This First Amendment to the Securities Purchase Agreement (this “Amendment”) is entered into on August 8, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser” and collectively with all other purchasers i |
|
| November 15, 2017 |
BIEI / Premier Biomedical Inc NT 10-Q bieint10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: 000-54563 Washington, D.C. 20549 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on For |
|
| October 24, 2017 |
BIEI / Premier Biomedical Inc ESP bieicorresp.htm October 24, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-220268 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned President of Premier Biomedical, Inc. hereby reque |
|
| October 16, 2017 |
Form of 8% Convertible Promissory Note, dated October 30, 2017 EXHIBIT 10.59 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| October 16, 2017 |
BIEI / Premier Biomedical Inc ESP bieicorresp.htm October 16, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Chris Edwards Re: Premier Biomedical, Inc. Amendment No. 1 to the Registration Statement on Form S-1 File No. 333-218250 Dear Mr. Edwards: The following responses of Premier Biomedical, Inc. (the ?Company?) are being provided in response to |
|
| October 16, 2017 |
As filed with the Securities and Exchange Commission on October 1 6 , 2017 As filed with the Securities and Exchange Commission on October 1 6 , 2017 Registration No. |
|
| October 4, 2017 |
BIEI / Premier Biomedical Inc ESP bieicorresp.htm October 4, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Chris Edwards Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-218250 Dear Mr. Edwards: The following responses of Premier Biomedical, Inc. (the ?Company?) are being provided in response to your comment letter dat |
|
| October 4, 2017 |
As filed with the Securities and Exchange Commission on October 4 , 2017 S-1/A 1 bieis1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on October 4 , 2017 Registration No. 333-220268 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or other jurisdicti |
|
| October 4, 2017 |
Form of 8% Convertible Promissory Note EX-10.59 3 bieiex1059.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.59 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT B |
|
| August 30, 2017 |
EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William A. Hartman, Heidi H. Carl and John Borza, and each of them, his or her true and lawful attorneys-in-fact and agents, each acting alone, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, i |
|
| August 30, 2017 |
As filed with the Securities and Exchange Commission on August 30, 2017 As filed with the Securities and Exchange Commission on August 30, 2017 Registration No. |
|
| August 21, 2017 |
Amendment No. 1 of the Securities Purchase Agreement, dated August 8, 2017 EXHIBIT 10.4 AMENDMENT NO. 1 SECURITIES PURCHASE AGREEMENT This First Amendment to the Securities Purchase Agreement (this “Amendment”) is entered into on August 8, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and the purchaser identified on the signature pages hereto (including its successors and assigns, the “Purchaser” and collectively with all other purchasers i |
|
| August 21, 2017 |
Amendment No. 1 of the Registration Rights Agreement, dated August 4, 2017 EX-10.3 4 bieiex103.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.3 AMENDMENT NO. 1 REGISTRATION RIGHTS AGREEMENT This First Amendment to the Registration Rights Agreement (this “Amendment”) is entered into on August 4, 2017 between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (including its successors and assigns, the “Purchase |
|
| August 21, 2017 |
BIEI / Premier Biomedical Inc FORM 10-Q (Quarterly Report) 10-Q 1 biei10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File |
|
| August 21, 2017 |
Form of 8% Convertible Promissory Note, dated August 8, 2017 EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| August 21, 2017 |
Form of Exchange Agreement, dated August 4, 2017 EXHIBIT 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is entered into on August 8, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”) and [•] (the “Shareholder”). Any capitalized terms not defined herein shall have the meaning given to such term in the Securities Purchase Agreement. RECITALS WHEREAS, pursuant to a Securities Purchase Agreement b |
|
| August 14, 2017 |
bieint10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: 000-54563 Washington, D.C. 20549 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2017 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11- |
|
| July 22, 2017 |
bieirw.htm July 21, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Re: Premier Biomedical, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-218250 Ladies and Gentlemen: Pursuant to Rule 477 of the Securities Act of 1933, as amended (the ?Securities Act?), Premier Biomedical, Inc. (the ?Company?) |
|
| July 12, 2017 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2017 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Com |
|
| July 6, 2017 |
As filed with the Securities and Exchange Commission on July 6 , 2017 As filed with the Securities and Exchange Commission on July 6 , 2017 Registration No. |
|
| May 26, 2017 |
EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William A. Hartman, Heidi H. Carl and John Borza, and each of them, his or her true and lawful attorneys-in-fact and agents, each acting alone, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, i |
|
| May 26, 2017 |
Form of Series B Common Stock Purchase Warrant EX-4.2 3 bieiex42.htm SERIES B COMMON STOCK PURCHASE WARRANT EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY N |
|
| May 26, 2017 |
As filed with the Securities and Exchange Commission on May 25, 2017 As filed with the Securities and Exchange Commission on May 25, 2017 Registration No. |
|
| May 26, 2017 |
Form of Registration Rights Agreement, dated March 30, 2017 EXHIBIT 10.54 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is entered into on March 30, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is entered into pursuant to the Securities Purch |
|
| May 26, 2017 |
Form of Series A Common Stock Purchase Warrant EX-4.1 2 bieiex41.htm SERIES A COMMON STOCK PURCHASE WARRANT EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY N |
|
| May 26, 2017 |
Form of Securities Purchase Agreement, dated March 30, 2017 EX-10.53 5 bieiex1053.htm SECURITIES PURCHASE AGREEMENT EXHIBIT 10.53 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2017, between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “P |
|
| May 23, 2017 |
bieirw.htm May 23, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Re: Premier Biomedical, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-218083 Ladies and Gentlemen: Pursuant to Rule 477 of the Securities Act of 1933, as amended (the ?Securities Act?), Premier Biomedical, Inc. (the ?Company?) r |
|
| May 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 22, 2017 |
Premier Biomedical FORM 10-Q (Quarterly Report) biei10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-5456 |
|
| May 18, 2017 |
Form of Series A Common Stock Purchase Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 18, 2017 |
Form of Registration Rights Agreement EX-10.54 6 bieiex1054.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.54 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into on March 30, 2017 by and between Premier Biomedical, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Ag |
|
| May 18, 2017 |
EX-24.1 8 bieiex241.htm POWER OF ATTORNEY EXHIBIT 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William A. Hartman, Heidi H. Carl and John Borza, and each of them, his or her true and lawful attorneys-in-fact and agents, each acting alone, with full power of substitution and resubstitution, for such person |
|
| May 18, 2017 |
Form of Series B Common Stock Purchase Warrant EX-4.2 3 bieiex42.htm SERIES B COMMON STOCK PURCHASE WARRANT EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY N |
|
| May 18, 2017 |
Form of Securities Purchase Agreement Exhibit 10.53 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 30, 2017, between Premier Biomedical, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condition |
|
| May 18, 2017 |
As filed with the Securities and Exchange Commission on May 18, 2017 As filed with the Securities and Exchange Commission on May 18, 2017 Registration No. |
|
| May 15, 2017 |
bieint10q.htm UNITED STATES SEC File No: 000-54563 CUSIP No: 74048 K 10 4 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2017 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11 |
|
| May 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54563 Premier Biomedical, Inc. |
|
| April 5, 2017 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2017 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (C |
|
| March 31, 2017 |
bieint10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2016 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form |
|
| March 28, 2017 |
bieirw.htm March 28, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Re: Premier Biomedical, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-215900 Ladies and Gentlemen: Pursuant to Rule 477 of the Securities Act of 1933, as amended (the ?Securities Act?), Premier Biomedical, Inc. (the ?Company?) |
|
| February 3, 2017 |
As filed with the Securities and Exchange Commission on February 3, 2017 S-1 1 bieis1.htm FORM S-1 As filed with the Securities and Exchange Commission on February 3, 2017 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or other jurisdiction of incorporatio |
|
| January 3, 2017 |
Unregistered Sales of Equity Securities 8-K 1 biei8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of i |
|
| December 27, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIE |
|
| October 14, 2016 |
bieiex103.htm EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| October 14, 2016 |
bieiex101.htm EXHIBIT 10.1 WARRANT PURCHASE AGREEMENT This WARRANT PURCHASE AGREEMENT (this ?Agreement?), dated as of October 10, 2016, is entered into by and among Typenex Co-Investment, LLC, a Utah limited liability company (?Seller?), Redwood Management, LLC, a Florida limited liability company (?Buyer?), and Premier Biomedical, Inc., a Nevada corporation (?Company?), for the purchase by Buyer |
|
| October 14, 2016 |
bieiex102.htm EXHIBIT 10.2 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?) is dated October 10, 2016 (the ?Effective Date?), by and between Premier Biomedical, Inc. (the ?Company?) and Redwood Management, LLC (the ?Holder?). WHEREAS, the Holder beneficially owns and holds that certain Warrant to Purchase Shares of Common Stock, dated November 25, 2014 issued by the Company set forth o |
|
| October 14, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| September 23, 2016 |
bieiex991.htm EXHIBIT 99.1 Premier Biomedical and Advanced Technologies Solutions Form Pain Management Joint Venture to Treat Generalized, Neuropathic and Localized Pain With Natural Cannabis-Based Products El Paso, Texas, September 15, 2016 - Premier Biomedical, Inc. (OTCQB: "BIEI") announced today the signing of an agreement forming a joint venture company with Advanced Technologies Solutions (A |
|
| September 23, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation |
|
| September 21, 2016 |
bieiex992.htm EXHIBIT 99.2 Premier Biomedical and Advanced Technologies Solutions Form Pain Management Joint Venture to Treat Generalized, Neuropathic and Localized Pain With Natural Cannabis-Based Products El Paso, Texas, September 15, 2016 - Premier Biomedical, Inc. (OTCQB: "BIEI") announced today the signing of an agreement forming a joint venture company with Advanced Technologies Solutions (A |
|
| September 21, 2016 |
Premier Biomedical Appoints Dr. Patricio Reyes to Board and Chief Technical Officer bieiex991.htm EXHIBIT 99.1 Premier Biomedical Appoints Dr. Patricio Reyes to Board and Chief Technical Officer El Paso, Texas, August 22, 2016 - Premier Biomedical, Inc. (OTCQB: "BIEI") announced the appointment of Dr. Patricio F. Reyes to its Board of Directors and to the position of Chief Technical Officer (CTO) effective immediately He will report to Premier?s President and CEO, William A. Hart |
|
| September 21, 2016 |
biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) ( |
|
| August 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER BIO |
|
| August 15, 2016 |
UNITED STATES SEC File No: 000-54563 CUSIP No: 74048 K 10 4 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 8, 2016 |
CORRESP 1 filename1.htm July 8, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-212235 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned President of Premier Biomedical, Inc. hereby r |
|
| July 8, 2016 |
As filed with the Securities and Exchange Commission on July 8, 2016 bieis1a.htm As filed with the Securities and Exchange Commission on July 8, 2016 Registration No. 333-212235 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or other jurisdiction of inc |
|
| June 24, 2016 |
As filed with the Securities and Exchange Commission on June 24, 2016 As filed with the Securities and Exchange Commission on June 24, 2016 Registration No. |
|
| June 20, 2016 |
bieiposam.htm As filed with the Securities and Exchange Commission on June 20, 2016 Registration No. 333-209125 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or othe |
|
| June 3, 2016 |
Registration Rights Agreement dated May 27, 2016 with Redwood Management, LLC EX-10.2 3 bieiex102.htm REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of May 27, 2016, between Premier Biomedical, Inc., a Nevada corporation (the "Company"), and Redwood Management, LLC a Florida limited liability company (together with its permitted assigns, (the "Buyer"). Capitalized ter |
|
| June 3, 2016 |
Stock Purchase Agreement dated May 27, 2016 with Redwood Management, LLC bieiex101.htm EXHIBIT 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this "Agreement") is dated as of May 27, 2016, by and between Premier Biomedical, Inc., a Nevada corporation (the "Company"), and Redwood Management, LLC, a Florida limited liability company (the "Investor"). WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the |
|
| June 3, 2016 |
biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Com |
|
| June 3, 2016 |
Convertible Promissory Note dated May 27, 2016 with Redwood Management, LLC bieiex103.htm EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54563 PREMIER BIOM |
|
| April 13, 2016 |
BIEI / Premier Biomedical Inc / Typenex Co-Investment, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Premier Biomedical Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 74048K104 (CUSIP Number) April 13, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| April 6, 2016 |
Up to 18,600,000 shares of common stock Filed pursuant to Rule 424(b)(3) Registration No. 333-209125 PROSPECTUS Up to 18,600,000 shares of common stock We are hereby registering 18,600,000 shares, representing approximately 14% of our fully-diluted outstanding common stock if warrants held by our directors are exercised and all notes are sold and converted into common stock, for sale by Redwood Management, LLC, a Florida limited liabili |
|
| April 4, 2016 |
bieicorresp.htm April 4, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-209125 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned President of Premier Biomedical, Inc. hereby requests |
|
| April 1, 2016 |
April 1, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| April 1, 2016 |
As filed with the Securities and Exchange Commission on April 1, 2016 S-1/A 1 bieis1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on April 1, 2016 Registration No. 333-209125 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Third Amended FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Premier Biomedical, Inc. (Exact name of registrant as specified in its charter) Nevada 2836 27-2635666 (State or other |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 000-54563 Premier Biomedical, Inc. |
|
| March 28, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (C |
|
| March 28, 2016 |
bieicorresp.htm March 28, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-209125 Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on March 25, 2016, in which we requested |
|
| March 25, 2016 |
bieicorresp.htm March 25, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Suzanne Hayes Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-209125 Dear Ms. Hayes: On behalf of Premier Biomedical, Inc. (the "Company'), we have filed today a Second Amended Registration Statement on Form S-1 f |
|
| March 25, 2016 |
As filed with the Securities and Exchange Commission on March 25, 2016 As filed with the Securities and Exchange Commission on March 25, 2016 Registration No. |
|
| March 25, 2016 |
bieicorresp.htm March 25, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-209125 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned President of Premier Biomedical, Inc. hereby request |
|
| March 16, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (C |
|
| March 16, 2016 |
10% CONVERTIBLE PROMISSORY NOTE DUE DECEMBER 11, 2016 EX-10.1 2 bieiex101.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE O |
|
| March 15, 2016 |
bieicorresp.htm March 15, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Suzanne Hayes Re: Premier Biomedical, Inc. Registration Statement on Form S-1 File No. 333-209125 Dear Ms. Hayes: On behalf of Premier Biomedical, Inc. (the "Company'), we herein provide the following responses to the Commission Staff comment |
|
| March 15, 2016 |
As filed with the Securities and Exchange Commission on March 15, 2016 As filed with the Securities and Exchange Commission on March 15, 2016 Registration No. |
|
| March 15, 2016 |
Convertible Promissory Note dated March 11, 2016 with Redwood Management, LLC EXHIBIT 10.46 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| March 11, 2016 |
First Amendment to Securities Purchase Agreement dated February 22, 2016 bieiex101.htm EXHIBIT 10.1 FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT This First Amendment to Securities Purchase Agreement (this "Amendment") is entered into on February 22, 2016 by and between Premier Biomedical, Inc., a Nevada corporation (the "Company") and Redwood Management, LLC (the "Purchaser"). RECITALS WHEREAS, the Company and Purchaser are parties to that certain Securities Purcha |
|
| March 11, 2016 |
Second Amendment to Securities Purchase Agreement dated March 7, 2016 bieiex102.htm EXHIBIT 10.2 SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT This Second Amendment to Securities Purchase Agreement (this "Amendment") is entered into on March 7, 2016 by and between Premier Biomedical, Inc., a Nevada corporation (the "Company") and Redwood Management, LLC (the "Purchaser"). RECITALS WHEREAS, the Company and Purchaser are parties to that certain Securities Purchase |
|
| March 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2016 |
Convertible Promissory Note dated March 7, 2016 with Redwood Management, LLC bieiex103.htm EXHIBIT 10.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| March 3, 2016 |
Convertible Promissory Note dated February 22, 2016 with Redwood Management, LLC bieiex101.htm EXHIBIT 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| March 3, 2016 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| February 17, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| February 10, 2016 |
Amendment to Articles of Incorporation of Premier Biomedical, Inc. bieiex31.htm EXHIBIT 3.1 Page 1 of 2 Page 2 of 2 |
|
| February 10, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| January 26, 2016 |
As filed with the Securities and Exchange Commission on January 26, 2016 As filed with the Securities and Exchange Commission on January 26, 2016 Registration No. |
|
| January 15, 2016 |
bieidef14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) x Definitive Information Statement PREM |
|
| January 12, 2016 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) ( |
|
| January 12, 2016 |
Convertible Promissory Note dated January 8, 2016, with Redwood Fund III Ltd. bieiex101.htm EXHIBIT 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| January 4, 2016 |
bieipre14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) ? Definitive Information Statement PREM |
|
| January 4, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2016 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| December 31, 2015 |
Securities Purchase Agreement dated December 28, 2015 with Redwood Management, LLC bieiex101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of December 28, 2015, between Premier Biomedical, Inc. (the "Company") and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively, the "Purchasers"). WHEREAS, subject to the terms and conditions set f |
|
| December 31, 2015 |
Registration Rights Agreement dated December 28, 2015 with Redwood Management, LLC bieiex103.htm EXHIBIT 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of December 28, 2015, between Premier Biomedical Inc., a Nevada corporation (the "Company"), and the purchaser signatory hereto (the "Purchaser"). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Com |
|
| December 31, 2015 |
Convertible Promissory Note dated December 28, 2015 with Redwood Management, LLC bieiex102.htm EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E |
|
| December 31, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 biei8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of |
|
| November 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIE |
|
| November 16, 2015 |
bieint10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048 K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2015 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on For |
|
| October 27, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) pdfproof.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):October 21, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| October 23, 2015 |
EXHIBIT 7.3 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 23, 2015 |
EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("THE ACT"), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 23, 2015 |
EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("THE ACT"), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 23, 2015 |
BIEI / Premier Biomedical Inc / ROSEN JAY PRESTON - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name, Address and Telephone Number |
|
| October 22, 2015 |
EXHIBIT 7.3 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 22, 2015 |
EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 22, 2015 |
EX-7.3 4 bieiex73.htm WARRANT DATED DECEMBER 10, 2014 EXHIBIT 7.3 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STA |
|
| October 22, 2015 |
EX-7.2 3 bieiex72.htm WARRANT DATED SEPTEMBER 28, 2012 EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION ST |
|
| October 22, 2015 |
EX-7.1 2 bieiex71.htm WARRANT DATED JUNE 21, 2010 EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEME |
|
| October 22, 2015 |
BIEI / Premier Biomedical Inc / Hartman William A. - SC 13D Activist Investment SC 13D 1 bieisc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name |
|
| October 22, 2015 |
EX-7.5 6 bieiex75.htm WARRANT DATED OCTOBER 7, 2015 EXHIBIT 7.5 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATE |
|
| October 22, 2015 |
EX-7.4 5 bieiex74.htm WARRANT DATED DECEMBER 10, 2014 EXHIBIT 7.4 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STA |
|
| October 22, 2015 |
EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 22, 2015 |
EXHIBIT 7.4 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 22, 2015 |
BIEI / Premier Biomedical Inc / Carl Heidi H. - SC 13D Activist Investment SC 13D 1 bieisc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name |
|
| October 20, 2015 |
EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
EXHIBIT 7.5 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
preex71.htm EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (?THE ACT?), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE ST |
|
| October 20, 2015 |
EXHIBIT 7.3 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
EXHIBIT 7.3 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
BIEI / Premier Biomedical Inc / Najarian Richard Thomas - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name, Address and Telephone Number |
|
| October 20, 2015 |
EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
BIEI / Premier Biomedical Inc / FELDER MITCHELL S - SC 13D Activist Investment SC 13D 1 bieisc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name |
|
| October 20, 2015 |
Premier Biomedical SC 13D (Activist Acquisition of More Than 5% of Shares) presc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Premier Biomedical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74048K104 (CUSIP Number) Brian A. Lebrecht c/o Clyde Snow & Sessions, P.C. 201 South Main Street, Suite 1300 Salt Lake City, UT 84111 (Name, Address and Tel |
|
| October 20, 2015 |
EXHIBIT 7.4 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
preex72.htm EXHIBIT 7.2 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (?THE ACT?), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE ST |
|
| October 20, 2015 |
EXHIBIT 7.4 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
EXHIBIT 7.1 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 20, 2015 |
EXHIBIT 7.5 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (i |
|
| October 6, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| September 23, 2015 |
Securities Purchase Agreement dated September 3, 2015 with Vis Vires Group, Inc. bieiex101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of September 3, 2015, by and between PREMIER BIOMEDICAL, INC., a Nevada corporation, with headquarters located at P.O. Box 31374, El Paso, TX 79930 (the ?Company?), and VIS VIRES GROUP, INC., a New York corporation, with its address at 111 Great Neck Road ? Suite 216, Great Neck, |
|
| September 23, 2015 |
Convertible Promissory Note dated September 3, 2015 with Vis Vires Group, Inc. EX-10.2 3 bieiex102.htm CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABS |
|
| September 23, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation |
|
| September 14, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| September 9, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) |
|
| September 9, 2015 |
Convertible Promissory Note dated September 2, 2015 bieiex101.htm EXHIBIT 10.1 San Diego, CA Miami, FL BIEI TERM SUMMARY CONVERTIBLE PROMISSORY NOTE Maturity: 2 years Financing: Up to $225,000 with $50,000 net wire amount at closing; up to $175,000 upon mutual consent Interest: Interest free if pre-paid within 90 days; otherwise, a 12% one-time interest charge Origination: 10% Original Issue Discount (OID) on actual payments made Warrants: None Con |
|
| August 20, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) biei8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) ( |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER BIO |
|
| August 14, 2015 |
Common Stock Purchase Warrant issued to Ryan Fields dated March 30, 2015 EXHIBIT 10.4 PREMIER BIOMEDICAL, INC. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, ( |
|
| July 9, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 9, 2015 |
Consulting Agreement with FBROCCO dated June 23, 2015 EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement is entered into as of June 23, 2015 (the "Effective Date") and is by and between Premier Biomedical, Inc., a Nevada corporation (the "Company"), whose mailing address is P.O. Box 31374, El Paso, Texas 79930, and FBROCCO ASSESSORIA EMPRESARIAL LTDA ASSESSORIA EMPRESARIAL LTDA, a Brazilian company (the "Consultant"), having its principal of |
|
| June 23, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 23, 2015 |
Amendment No. 1 to Patent License Agreement dated June 19, 2015. EXHIBIT 10.2 |
|
| May 15, 2015 |
Common Stock Purchase Warrant dated March 20, 2015 EXHIBIT 10.7 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICA |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIER BI |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-54563 Premier Biomedical, Inc |
|
| March 18, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 18, 2015 |
Patent License Agreement dated March 4, 2015 EX-10.1 2 bieiex101.htm PATENT LICENSE AGREEMENT EXHIBIT 10.1 PATENT LICENSE AGREEMENT (UTEP AND PREMIER BIOMEDICAL, INC.) This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”). No binding agreement between the Parties regarding a Patent License will exist until this Patent License Agreement has been signed by both Par |
|
| March 6, 2015 |
Premier Biomedical FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 6, 2015 |
Amendment to Note dated March 4, 2015 EXHIBIT 10.4 AMENDMENT This Amendment (this ?Amendment?) is entered into as of March 4, 2015, by and between Typenex Co-Investment, LLC, a Utah corporation (?Lender?), and Premier Biomedical, Inc., a Nevada corporation (?Borrower?). Any capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the Note (as defined below). A. Borrower previously issue |
|
| March 6, 2015 |
PREMIER BIOMEDICAL, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK EXHIBIT 10.3 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STAT |
|
| March 4, 2015 |
Securities Purchase Agreement dated February 24, 2015 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 24, 2015, by and between Premier Biomedical, Inc., a Nevada corporation, with headquarters located at P.O. Box 31374, El Paso, TX 79930 (the “Company”), and ADAR BAYS, LLC, a Florida limited liability company, with its address at 3411 Indian Creek Drive, Suite 403, Miami Beach, FL |
|
| March 4, 2015 |
Convertible Promissory Note dated February 24, 2015 EXHIBIT 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”) US $44,10 |
|
| March 4, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 4, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2015 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| February 4, 2015 |
Securities Purchase Agreement dated January 30, 2015 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 29, 2015, by and between Premier Biomedical, Inc., a Nevada corporation, with headquarters located at P.O. Box 31374, El Paso, TX 79930 (the “Company”), and LG CAPITAL FUNDING, LLC, a New York limited liability company, with its address at 1218 Union Street, Suite #2, Brooklyn, NY 1 |
|
| February 4, 2015 |
Convertible Promissory Note dated January 30, 2015 EXHIBIT 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”) US $82,68 |
|
| December 12, 2014 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2014 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commissio |
|
| December 2, 2014 |
Convertible Promissory Note dated November 25, 2014 EXHIBIT 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATIO |
|
| December 2, 2014 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2014 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| December 2, 2014 |
Securities Purchase Agreement dated November 25, 2014 EX-10.1 2 bieiex101.htm SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of November 25, 2014, is entered into by and between Premier Biomedical, Inc., a Nevada corporation (“Company”), and Typenex Co-Investment, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and I |
|
| November 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-54563 PREMIE |
|
| November 14, 2014 |
BIEI / Premier Biomedical Inc NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File No: 000-54563 CUSIP No: 74048K 10 4 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2014 ¨ Transition report on Form 10-K ¨ Transition report on Form 20-F ¨ Transition report on Form 11-K ¨ Transi |
|
| November 10, 2014 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2014 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| October 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2014 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commission |
|
| September 26, 2014 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 PREMIER BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 000-54563 27-2635666 (State or other jurisdiction of incorporation) (Commissi |
